Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies

NCT05004337 — Completed, 136 participants, Natera, Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies (VANISH)

RegistryNCT05004337, acronym VANISH
StatusCompleted
Study typeObservational
Enrollment136 (Actual)
SponsorNatera, Inc. (Industry)
ConditionsVanishing Twin, Trisomy 21, Trisomy 13, Trisomy 18
Datesstart 2021-07-22, primary completion 2023-11-29, completion 2023-11-29, first posted 2021-08-13, last updated 2026-08-17
Locations21 sites in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Vanishing Twin All trials for Trisomy 21

-Summary

The purpose of this study is to collect blood samples from women carrying a vanishing twin pregnancy to further develop Natera's non-invasive prenatal screening test to provide information about possible chromosomal conditions for the living twin

Expand all sections  ·  Collapse all

+Outcome measures

Primary outcomes

  • Develop a new algorithm and methodology that will measure fetal fraction and distinguish between the DT (demised/non-viable twin) and living twin (LT) in dizygotic twins (DZ) with a single LT. [2 years]: A new algorithm will be written to analyze the serial research blood samples to return a fetal fraction of each twin, and identify which twin is the DT verses the LT. The fetal fraction measurement will be a percentage, and it will be measurable, or not measurable for each sample.
  • The accuracy of the new algorithm to determine which of the signals in the Panorama samples correspond to the LT versus the DT. [2 Years]: Each complete participant in the study will have multiple maternal blood samples collected, and a child buccal swab. This outcome will use genetic analysis to reflect for each participant if the algorithm correctly or incorrectly identified the LT versus the DT. Accuracy, defined as the number of VT pairs correctly identified as the LT and DT, divided by the total number of VT pairs, will be calculated.

Secondary outcomes

  • The accuracy of the updated algorithm for the assignment of risk for trisomy 21/18/13 for the LT in DZ twins with a single LT. [3 Years]: If a sufficient number of trisomy 21/18/13 cases are observed among any of the cases, assess the accuracy of the updated algorithm to correctly determine whether the LT or DT is aneuploidy. Point estimates and 95% confidence intervals for the specificity for the aneuploidy algorithm.

+Eligibility

Sex: Female, ages: 18 Years to any

Inclusion Criteria:

* Women with either ultrasound-documented dizygotic (DZ) twin pregnancy or those whose Panorama Testâ„¢ results suggest increased risk for vanishing twin

Exclusion Criteria:

* Monozygotic twin pregnancy
* Non twin pregnancy
* Maternal history of bone marrow or organ transplantation

+Locations (21)

FacilityCityCountryStatus
Center for Fetal Medicine & Women's UltrasoundLos Angeles, CaliforniaUnited States
StanfordPalo Alto, CaliforniaUnited States
University of ColoradoAurora, ColoradoUnited States
YaleNew Haven, ConnecticutUnited States
Christiana CareNewark, DelawareUnited States
Emerald Coast ObGynPanama City, FloridaUnited States
University of KansasKansas City, KansasUnited States
University of MichiganAnn Arbor, MichiganUnited States
BeaumontRoyal Oak, MichiganUnited States
Mayo ClinicRochester, MinnesotaUnited States
HackensackNeptune City, New JerseyUnited States
St. Peter's University HospitalNew Brunswick, New JerseyUnited States
NYU Long IslandMineola, New YorkUnited States
NYU LangoneNew York, New YorkUnited States
Icahn School of Medicine at Mount Sinai HospitalNew York, New YorkUnited States
Columbia UniversityNew York, New YorkUnited States
Weill Cornell MedicineNew York, New YorkUnited States
Montefiore Medical CenterThe Bronx, New YorkUnited States
Lehigh Valley Health NetworkAllentown, PennsylvaniaUnited States
University of PennsylvaniaPhiladelphia, PennsylvaniaUnited States
Cedar Health ResearchIrving, TexasUnited States

+Investigators